Amgen (AMGN) Common Equity (2009 - 2026)

Amgen has reported Common Equity for 18 years, with the latest figure at $9.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 48.06% year-over-year to $9.2 billion; the trailing twelve-month figure through Mar 2026 stood at $9.2 billion (up 48.06% YoY), and the FY2025 full-year result was $8.7 billion, up 47.32% from the prior year.
• Common Equity for Q1 2026 stood at $9.2 billion, up from $8.7 billion in the prior quarter.
• The five-year high for Common Equity was $9.6 billion in Q3 2025, with the low at $916.0 million in Q1 2022.
• Average Common Equity over 5 years is $6.0 billion, with a median of $6.2 billion recorded in 2025.
• Year-over-year, Common Equity slumped 90.19% in 2022 and surged 483.84% in 2023.
• Tracing AMGN's Common Equity over 5 years: stood at $3.7 billion in 2022, then jumped by 70.23% to $6.2 billion in 2023, then slipped by 5.7% to $5.9 billion in 2024, then jumped by 47.32% to $8.7 billion in 2025, then advanced by 6.14% to $9.2 billion in 2026.
• The last three Common Equity figures came in at $9.2 billion (Q1 2026), $8.7 billion (Q4 2025), and $9.6 billion (Q3 2025), per Business Quant data.

Peer Comparison